Biomea Fusion completes enrollment in Phase II COVALENT-211 diabetes trial
Biomea Fusion (BMEA) announces completion of enrollment in the COVALENT-211 Phase II trial of icovamenib in insulin-deficient Type 2 diabetes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.